-
公开(公告)号：US20240360172A1
公开(公告)日：2024-10-31
申请号：US18756504
申请日：2024-06-27
Applicant: Lakewood Amedex, Inc.
Inventor： Randolph B. Sleet , Steven A. Kates , Steven Parkinson
Abstract: A method of treating an infection of a lung in a patient in need thereof according to an embodiment includes administering to the patient an effective amount of a compound having the formula:
or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US12030908B2
公开(公告)日：2024-07-09
申请号：US17856537
申请日：2022-07-01
Applicant: Lakewood Amedex, Inc.
Inventor： Randolph B. Sleet , Steven A. Kates , Steven Parkinson
Abstract: A method of treating an infection of a lung in a patient in need thereof according to an embodiment includes administering to the patient an effective amount of a compound having the formula:
or a pharmaceutically acceptable salt thereof.-
公开(公告)号：US20240148729A1
公开(公告)日：2024-05-09
申请号：US18216937
申请日：2023-06-30
Applicant: DOUGLAS PHARMACEUTICALS LIMITED
Inventor： Ian Hampson , Lynne Hampson
IPC: A61K31/513 , A61K9/00 , A61K9/06 , A61K31/427 , A61K47/38 , A61P15/02
CPC classification number: A61K31/513 , A61K9/0034 , A61K9/06 , A61K31/427 , A61K47/38 , A61P15/02
Abstract: The present invention concerns pharmaceutical compositions formulated for topical application that are useful in the treatment of HPV-related pathologies and in particular the treatment of premalignant and malignant conditions of the cervix. The compositions comprise a therapeutically effective amount of lopinavir and ritonavir in a pharmaceutically acceptable vehicle and wherein the weight ratio (w/w) of lopinavir:ritonavir is between 9:1 and 18:1.
-
公开(公告)号：US20240091152A1
公开(公告)日：2024-03-21
申请号：US18519851
申请日：2023-11-27
Applicant: The Materia Company Limited
Inventor： Matthaios VIDALIS
IPC: A61K9/12 , A61K9/00 , A61K9/14 , A61K31/4164 , A61K31/4706 , A61K31/69 , A61K33/22 , A61P15/00 , A61P15/02
CPC classification number: A61K9/124 , A61K9/0034 , A61K9/12 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/148 , A61K31/4164 , A61K31/4706 , A61K31/69 , A61K33/22 , A61P15/00 , A61P15/02
Abstract: An intravaginal formulation comprising a dry powder composition and propellant(s) and the apparatus capable of delivery intravaginally a dry powder composition.
-
公开(公告)号：US20230414505A1
公开(公告)日：2023-12-28
申请号：US18233560
申请日：2023-08-14
Applicant: ProFem GmbH
Inventor： Marion NOE , Christian R. NOE
IPC: A61K9/107 , A61P15/02 , A61P31/04 , A61K31/196 , A61K9/10 , A61K31/4174 , A61K47/22
CPC classification number: A61K9/107 , A61P15/02 , A61P31/04 , A61K9/0014 , A61K9/10 , A61K31/4174 , A61K47/22 , A61K31/196
Abstract: The invention relates to an emulsion, e.g. in the form of a salve or a cream, with an aqueous phase and an oil phase, containing an NSAID, characterised in that: (a) the NSAID in the aqueous phase is in a concentration range that corresponds to half to a tenth of the standard concentration for these active substances; (b) the weight ratio of the water-to-oil phase in said emulsion is between the values 2.0 and 2.7; and (c) the pH value of the emulsion is not below the value 6.5 and not above 8.5, preferably in the region of between 7.0 and 8.0, particularly for application in the topical treatment of vaginal fungal infections.
-
Patent Agency Ranking
公开(公告)号：US11850304B2
公开(公告)日：2023-12-26
申请号：US17042555
申请日：2019-03-28
Applicant: The Materia Company Limited
Inventor： Matthaios Vidalis
IPC: A61K9/12 , A61K9/00 , A61K9/14 , A61K31/4164 , A61K31/4706 , A61K31/69 , A61K33/22 , A61P15/00 , A61P15/02
CPC classification number: A61K9/124 , A61K9/0034 , A61K9/12 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/148 , A61K31/4164 , A61K31/4706 , A61K31/69 , A61K33/22 , A61P15/00 , A61P15/02
Abstract: An intravaginal formulation comprising a dry powder composition and propellant(s) and the apparatus capable of delivery intravaginally a dry powder composition.
-
公开(公告)号：US11819554B2
公开(公告)日：2023-11-21
申请号：US15760765
申请日：2016-09-16
Applicant: University of Massachusetts
Inventor： Michael R. Green , Minggang Fang , Walter Kowtoniuk
IPC: A61K31/711 , A61K35/30 , A61K38/45 , A61K38/53 , A61K39/395 , A61K48/00 , A61K31/5377 , A61K31/549 , A61K31/706 , A61K31/713 , C12Q1/6883 , C12N15/113 , A61K31/7088 , A61K31/404 , A61K31/546 , A61K31/167 , A61K31/497 , A61K31/506 , A61K31/437 , A61K31/4406 , A61K31/522 , A61K31/496 , A61P25/14 , A61P15/02 , A61K31/7105
CPC classification number: A61K48/005 , A61K31/167 , A61K31/404 , A61K31/437 , A61K31/4406 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/522 , A61K31/5377 , A61K31/546 , A61K31/549 , A61K31/706 , A61K31/7088 , A61K31/711 , A61K31/713 , A61K31/7105 , A61K35/30 , A61K38/45 , A61K38/53 , A61K39/3955 , A61K48/0016 , A61P15/02 , A61P25/14 , C12N15/113 , C12Q1/6883 , C12N2310/11 , C12N2310/14 , C12N2310/141 , C12N2310/531 , C12Q2600/154 , C12Q2600/158 , C12Y201/01037 , C12Y201/01043 , C12Y603/02019
Abstract: The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1-inactivation-associated disorder (e.g., fragile X syndrome).
-
公开(公告)号：US20230346724A1
公开(公告)日：2023-11-02
申请号：US17300191
申请日：2019-10-08
Applicant: Crapaud Bio Inc.
Inventor： J. McLeod Griffiss
IPC: A61K31/192 , A61K9/00 , A61K47/36 , A61K31/194 , A61P15/02 , A61K33/00 , A61K47/10
CPC classification number: A61K31/192 , A61K9/0034 , A61K47/36 , A61K31/194 , A61P15/02 , A61K33/00 , A61K47/10
Abstract: The present invention relates generally to compositions (e.g., gels, suppositories, and the like) and methods for modulating the acidity and/or alkalinity of the fluidic environment of human reproductive organs and systems (e.g., vagina, and cervical fluids/mucus). In particular, the compositions and methods of the present invention are useful for modulating the acidity and/or alkalinity of the fluids within the vagina and that bathe the mucosal surfaces therein. The compositions and methods are useful for promoting and/or sustaining colonization of the vagina by beneficial and/or typically nonpathogenic species of commensal microorganisms (e.g., bacterial species). Additionally, the compositions and methods are useful as adjuvants and/or carriers for introducing one or more species of beneficial commensal microorganisms (e.g., bacterial species) into the vagina such as lactic acid producing bacteria, and in particular, species of Lactobacilli.
-
公开(公告)号：US11779538B2
公开(公告)日：2023-10-10
申请号：US16763372
申请日：2018-11-14
Applicant: ProFem GmbH
Inventor： Marion Noe , Christian R. Noe
IPC: A61K9/10 , A61K9/107 , A61P15/02 , A61P31/04 , A61K31/196 , A61K31/4174 , A61K47/22 , A61K9/00 , A61K9/06 , A61K45/06
CPC classification number: A61K9/107 , A61K9/10 , A61K31/196 , A61K31/4174 , A61K47/22 , A61P15/02 , A61P31/04 , A61K9/0014 , A61K9/0034 , A61K9/06 , A61K45/06
Abstract: The invention relates to an emulsion, e.g. in the form of a salve or a cream, with an aqueous phase and an oil phase, containing an NSAID, characterised in that: (a) the NSAID in the aqueous phase is in a concentration range that corresponds to half to a tenth of the standard concentration for these active substances; (b) the weight ratio of the water-to-oil phase in said emulsion is between the values 2.0 and 2.7; and (c) the pH value of the emulsion is not below the value 6.5 and not above 8.5, preferably in the region of between 7.0 and 8.0, particularly for application in the topical treatment of vaginal fungal infections.
-
公开(公告)号：US20230255989A1
公开(公告)日：2023-08-17
申请号：US17970388
申请日：2022-10-20
Applicant: DSM Nutritional Products, LLC
Inventor： Geoffrey A. von Maltzahn , Yvonne J. Yamanaka
IPC: A61K31/702 , A61K45/06 , A61K31/715 , A61K31/733 , A61K31/716 , A61P1/02 , A61P15/02 , A61P31/04 , A61P11/02 , A61K8/60 , A61K8/73 , A61K8/99 , A61K9/00 , A61K35/741 , A61K35/742 , A61K35/744 , A61K35/745 , A61K35/747 , A61Q11/00
CPC classification number: A61K31/702 , A61K45/06 , A61K31/715 , A61K31/733 , A61K31/716 , A61P1/02 , A61P15/02 , A61P31/04 , A61P11/02 , A61K8/60 , A61K8/73 , A61K8/99 , A61K9/0034 , A61K9/0043 , A61K9/006 , A61K35/741 , A61K35/742 , A61K35/744 , A61K35/745 , A61K35/747 , A61Q11/00 , Y02A50/30 , A61K2035/115
Abstract: Compositions comprising glycan preparations suitable for local administration to non-gut sites containing mucosal tissue, e.g., oral cavity, nasal cavity and vagina are provided. Further provided are methods of using said glycan preparations.
-
-
-
-
-
-
-
-
-
Search Results
383
records
(took 0.021 seconds)
